Effect of montelukast and fluticasone propionate on airway mucosal blood flow in asthma

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Abstract

Asthma is associated with an increase in airway blood flow (Q̇aw), presumably as a manifestation of airway inflammation. We therefore determined the effect of the antiinflammatory agents montelukast (ML) and fluticasone propionate (FP) on Q̇aw in 12 patients with mild intermittent asthma. Using a double-blind approach, Q̇aw along with FEV1 and V̇max 50 were determined before and after a 2-week treatment period with either ML (10 mg/day), FP (440 μg/day), or 10 mg of ML plus 440 μg of FP daily, separated by 2-week washout periods. Mean (± SEM) Q̇aw ranged from 68 ± 4.2 to 71.8 ± 5.9 μl·minute -1·ml-1 anatomic dead space before the treatment periods. ML, FP, and ML plus FP decreased mean Q̇aw by 21.5, 20.8, and 26.9%, respectively (p < 0.05 for all). No significant difference was observed among the three regimens. FEV1 and V̇max50 were not changed by any of the treatments. We conclude that at the dosages used, ML and FP are equipotent in reducing Q̇aw in patients with mild asthma, and that the magnitude of the response is not greater if the two drugs are combined. The results also suggest that the vascular effects of these agents can be assessed independent of their effects on airway function.

Original languageEnglish (US)
Pages (from-to)1131-1134
Number of pages4
JournalAmerican journal of respiratory and critical care medicine
Volume169
Issue number10
DOIs
StatePublished - May 15 2004

Keywords

  • Airway inflammation
  • Asthma
  • Bronchial circulation
  • Glucocorticosteroids
  • Leukotriene modifiers

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Effect of montelukast and fluticasone propionate on airway mucosal blood flow in asthma'. Together they form a unique fingerprint.

Cite this